FDA Approves Lilly’s New Rapid-Acting Insulin, Lyumjev

On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with type 1 and type 2 diabetes.

 

Jet Equities detected the news event and sent an alert at 10:21 pm. The last trade was at 6:37 pm for $141.50. Eli Lilly’s stock price spiked higher at the market open on June 16 and continued to rise throughout the day. The stock closed at $163.71 for an event-day gain of 15.7%.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

Subscribe here if you would like to start receiving these signals in real-time and start trading!